Matrix metalloproteinase-9 (MMP9), Signal transducer and activator of transcription 3 (STAT3), and Prostaglandin-endoperoxide synthase 2 (PTGS2) (MMP9/STAT3/PTGS2)

This target entry represents a cluster of proteins—Matrix metalloproteinase-9 (MMP9), Signal transducer and activator of transcription 3 (STAT3), and Prostaglandin-endoperoxide synthase 2 (PTGS2)—that are central to the inflammatory interplay between obesity and asthma. MMP9 is a zinc-dependent endopeptidase that degrades extracellular matrix components, contributing to structural airway remodeling in chronic asthma [1]. STAT3 is a transcription factor that mediates signaling for pro-inflammatory cytokines like IL-6, which is often elevated in obese individuals; STAT3 activation directly promotes the transcription of both MMP9 and PTGS2 [2, 4]. PTGS2, or COX-2, is an inducible enzyme responsible for the synthesis of prostaglandins that drive acute and chronic inflammation [3]. Together, these proteins form a pathological axis where systemic metabolic inflammation (obesity) exacerbates local pulmonary inflammation (asthma) through shared signaling pathways [4]. Pharmacological intervention involves a variety of agents, including selective COX-2 inhibitors like Celecoxib, MMP inhibitors, and emerging STAT3 inhibitors such as Napabucasin [5]. Sources: [1] UniProt P14780; [2] UniProt P40763; [3] UniProt P35354; [4] PubMed 24613445; [5] DrugBank DB00482, DB12666.

Other names

Gelatinase B92 kDa type IV collagenaseAcute-phase response factorAPRFCyclooxygenase-2COX-2Prostaglandin G/H synthase 2

Inhibition of matrix metalloproteinase enzymatic activity (MMP9), inhibition of STAT3 phosphorylation and DNA binding (STAT3), and selective inhibition of cyclooxygenase-2 activity (PTGS2).